Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIR BIOTECHNOLOGY, INC.

(VIR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments to treat and prevent serious infectious diseases. Its technology platforms are focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid (siRNA). Its pipeline consists of product candidates targeting hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). Its product candidates include VIR-2218, VIR-3434, VIR-2482, VIR-1111 and VIR-2020. The Company is developing VIR-2218 and VIR-3434 for the functional cure of HBV. VIR-2218 is a subcutaneously administered HBV-targeting siRNA. VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody (mAb). VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb. VIR-1111 is a subcutaneously administered HIV T cell vaccine. VIR-2020 is a subcutaneously administered TB T cell vaccine.

Number of employees : 327 people.
Sales per Business
2020
USD (in Million)%
Contract44.5058.3%
License22.7529.8%
Grant9.1211.9%
Sales per region
20192020Delta
USD (in Million)%USD (in Million)%
United States8.09100%76.37100% +843.86%
Managers
NameAgeSinceTitle
George Scangos712017President, Chief Executive Officer & Director
Howard Horn432017CFO, Secretary & Principal Accounting Officer
Michael Kamarck692017Chief Technology Officer
Phil Pang452018Chief Medical Officer
Herbert Virgin642018Chief Scientific Officer & Executive VP-Research
Steven Rice-2020Chief Administrative Officer
Vicki Sato712016Non-Executive Chairman
Robert Taylor Nelsen572016Independent Director
Robert J. Perez562017Independent Director
Phillip A. Sharp, Dr.752017Independent Director
Members of the board
NameAgeSinceTitle
Vicki Sato712016Non-Executive Chairman
George Scangos712017President, Chief Executive Officer & Director
Robert Taylor Nelsen572016Independent Director
Robert J. Perez562017Independent Director
Phillip A. Sharp, Dr.752017Independent Director
Robert J. More532016Independent Director
Dipchand V. Nishar512017Independent Director
Sona Saira Ramasastry442019Independent Director
Charles Elliott Sigal, Dr.682020Independent Director
Janet Ann Napolitano632020Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 130,039,838 113,072,910 87.0% 0 0.0% 87.0%
Shareholders
NameEquities%
ARCH Venture Partners LLC 26,666,663 20.5%
SB Investment Advisers (UK) Ltd. 22,616,666 17.4%
Capital Research & Management Co. (International Investors) 11,822,763 9.09%
GlaxoSmithKline plc 6,626,027 5.10%
George Scangos 6,520,888 5.01%
Capital Research & Management Co. (World Investors) 5,867,608 4.51%
The Vanguard Group, Inc. 5,801,429 4.46%
Capital Research & Management Co. (Global Investors) 5,684,370 4.37%
Temasek Holdings Pte Ltd. (Investment Management) 5,518,644 4.24%
Baillie Gifford & Co. 3,817,148 2.94%
Company contact information
Vir Biotechnology, Inc.
499 Illinois Street
Suite 500
5th floor
San Francisco, CA 94158

Phone : +1.415.906.4324
Web : http://www.vir.bio
Sector Other Biotechnology & Medical Research
1st jan.Capitalization (M$)
VIR BIOTECHNOLOGY, INC.72.33%6 001
MODERNA, INC.90.67%79 980
LONZA GROUP LTD14.63%52 508
IQVIA HOLDINGS INC.33.76%45 934
CELLTRION, INC.-24.79%32 465
SEAGEN INC.-10.75%28 367
HANGZHOU TIGERMED CONSULTING CO., LTD14.49%24 102
PHARMARON BEIJING CO., LTD.62.65%23 432
CUREVAC N.V.-23.60%21 497
ALNYLAM PHARMACEUTICALS, INC.36.10%20 793
INCYTE CORPORATION-3.47%18 465
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.41.56%17 774
BIO-TECHNE CORPORATION36.01%16 797
PPD, INC.35.36%16 288
NOVAVAX, INC.56.24%12 918
ICON PUBLIC LIMITED COMPANY8.82%11 215
PRA HEALTH SCIENCES, INC.33.28%10 833
QIAGEN N.V.-10.84%10 763
CRISPR THERAPEUTICS AG-16.51%10 242
GENSCRIPT BIOTECH CORPORATION191.22%8 779
SYNEOS HEALTH, INC.23.94%8 746